Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2, Dose Escalation and Expansion Trial to Evaluate the Safety and Efficacy of Tegavivint in Patients With Metastatic Colorectal Carcinoma

Next Previous
Trial Profile

A Phase 1/2, Dose Escalation and Expansion Trial to Evaluate the Safety and Efficacy of Tegavivint in Patients With Metastatic Colorectal Carcinoma

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 03 Apr 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tegavivint (Primary) ; Antineoplastics
  • Indications Adenocarcinoma; Carcinoma; Colorectal cancer
  • Focus Adverse reactions

Most Recent Events

  • 25 Mar 2026 According to an Iterion Therapeutics media release, the first patient has been dosed at HonorHealth Research Institute in a phase 1/2 clinical trial evaluating tegavivint for the treatment of metastatic colorectal cancer (mCRC).
  • 17 Mar 2026 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top